Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-11-21
2006-11-21
Epps-Ford, Janet L. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093200, C435S320100, C435S325000, C435S455000
Reexamination Certificate
active
07138381
ABSTRACT:
Preparations of conjugates of a receptor-binding internalized ligand and a cytocide-encoding agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor, cytokine, or growth factor coupled to a nucleic acid binding domain. One or more linkers may be used in the conjugation. The linker is selected to increase the specificity, toxicity, solubility, serum stability, or intracellular availability, and promote nucleic acid condensation of the targeted moiety. The conjugates are complexed with a cytocide-encoding agent, such as DNA encoding saporin. Conjugates of a receptor-binding internalized ligand to a nucleic acid molecule are also provided.
REFERENCES:
patent: 5166320 (1992-11-01), Wu et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5308622 (1994-05-01), Casscells et al.
patent: 5354844 (1994-10-01), Beug et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5635383 (1997-06-01), Wu et al.
patent: 5679637 (1997-10-01), Lappi et al.
patent: 5707969 (1998-01-01), Nabel et al.
patent: 5830686 (1998-11-01), Henderson
patent: 5994109 (1999-11-01), Woo et al.
patent: 5997859 (1999-12-01), Barber et al.
patent: WO 90/12597 (1990-11-01), None
patent: WO 91/18012 (1991-11-01), None
patent: WO 92/04918 (1992-04-01), None
patent: WO 93/17669 (1993-09-01), None
patent: WO 93/25688 (1993-12-01), None
patent: WO 94/04696 (1994-03-01), None
patent: WO 94/25608 (1994-11-01), None
patent: WO 95/03831 (1995-02-01), None
patent: WO 95/22618 (1995-08-01), None
patent: WO 95/24928 (1995-09-01), None
patent: WO 95/28494 (1995-10-01), None
patent: WO 96/06641 (1996-03-01), None
patent: WO 96/08274 (1996-03-01), None
patent: WO 96/13599 (1996-05-01), None
Hoganson et al., “Comparison of the Effects of Three Different Toxin Genes and Their Levels of Expression on Cell Growth and Bystander Effect in Lung Adenocarcinoma,”Cancer Research 56(6):1315-1323, Mar. 15, 1996.
Kreitman et al., “A circularly permuted recombinant interleukin 4 toxin with increased activity,”Proc Natl Acad Sci U S A. 91(15):6889-6893, Jul. 19, 1994.
Ledley,Hum. Gene Ther. 6:1129-44, 1995.
Mastrangelo et al., “Gene therapy for human cancer: an essay for clinicians,”Seminars in Oncology 23(1):4-21, Feb. 1996.
Melton and Sherwood, “Antibody-enzyme conjugates for cancer therapy,”J. Natl. Cancer Inst. 88(3/4):153-165, Feb. 21, 1996.
Ngo et al., “The protein folding problem and tertiary structure function,” Birkhauser Boston Inc., 14, pp. 491-495, 1994.
Rieck et al.,Retinal Cell Biology/Cornea, Abstract No. 16823.
Sosnowski et al., “Receptor Mediated Gene Delivery Through the FGF Receptor: Applications in the Eye,”Investigative Ophthalmology&Visual Science 37(3):S187, Abstract No. 885, 1996.
Sosnowski et al., “Targeting DNA through fibroblast growth factor receptors,”Proceedings of the American Association for Cancer Research 37:426, Abstract No. 2911, Mar. 1996.
Stein et al., “The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3′-kinase,”Mol. Cell Biol. 14(5):3392-3402, May 1994.
Thorpe et al., “New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo,”Cancer Res. 47(22):5924-5931, Nov. 15, 1987.
Vile et al., “Strategies for achieving multiple layers of selectivity in gene therapy,”Molecular Medicine Today 4(2):84-92, Feb. 1998.
Wagner et al., “Transferrin-polycation conjugates as carriers for DNA uptake into cells,”Proc. Natl. Acad. Sci. USA 87(9):3410-3414, May 1990.
Westby et al., “Separation and Characterization of Recombinant Proricin Containing an Alternative Protease-Sensitive Linker Sequence,”Bioconjugate Chem. 3(5):375-381, Sep.—Oct. 1992.
Zenke et al., “Receptor-mediated endocytosis of transferrin-polycation conjugates: An efficient way to introduce DNA into hematopoietic cells,”Proc. Natl. Acad. Sci. USA 87(10):3655-3659, May 1990.
Bicknell,Analls of Oncology 5(Suppl. 4): S45-S50.
Chen et al., “A novel gene delivery system using EGF receptor-mediated endocytosis,”FEBS Letters 338(2):167-169, Jan. 31, 1994.
Chen et al., “Design of a genetic immunotoxin to eliminate toxin immunogenicity,”Gene Therapy 2(2):116-123, Mar. 1995.
Coglan,New Scientist, pp. 14-15, Nov. 1995.
Crystal, “Transfer of genes to humans: early lessons and obstacles to success,”Science 270(5235): 404-410, Oct. 20, 1995.
Dauchel et al., “Modulation of Mitogenic Acitivity and Cellular Binding of Basic Fibroblast Growth Factor by Basic Proteins,”Journal of Cellular Biochemistry 39(4):411-420, Apr. 1989.
Deonarain et al., “Targeting enzymes for cancer therapy: old enzymes in new roles,”British J. Cancer 70(5): 786-794, Nov. 1994.
Fattom et al., “Comparative Immunogenicity of Conjugates Composed of theStaphylococcus aureusType 8 Capsular Polysaccharide Bound to Carrier Proteins by Adipic Acid Dihydrazide or N-Succinimidyl-3-(2-Pyridyldithio) propionate,”Infection and Immunity 60(2):584-589, Feb. 1992.
Gunzberg et al.,Mol. Medicine Today 4:410-417, 1995.
Baird J. Andrew
Chandler Lois Ann
Sosnowski Barbara A.
Epps-Ford Janet L.
Prizm Pharmaceuticals, Inc.
Seed IP Law Group PLLC
LandOfFree
Compositions containing nucleic acids and ligands for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions containing nucleic acids and ligands for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions containing nucleic acids and ligands for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3697838